These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 31698455)

  • 21. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
    Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
    Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
    Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
    Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization.
    Hanssens H; Meeus F; De Vlaeminck Y; Lecocq Q; Puttemans J; Debie P; De Groof TWM; Goyvaerts C; De Veirman K; Breckpot K; Devoogdt N
    Front Immunol; 2024; 15():1389018. PubMed ID: 38720898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells].
    Zhong MJ; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):804-811. PubMed ID: 31775477
    [No Abstract]   [Full Text] [Related]  

  • 25. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
    Cohen AD
    Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
    Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
    Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
    [No Abstract]   [Full Text] [Related]  

  • 27. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 28. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
    Lin L; Cho SF; Xing L; Wen K; Li Y; Yu T; Hsieh PA; Chen H; Kurtoglu M; Zhang Y; Andrew Stewart C; Munshi N; Anderson KC; Tai YT
    Leukemia; 2021 Mar; 35(3):752-763. PubMed ID: 32632095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
    Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CARs in the Lead Against Multiple Myeloma.
    Ormhøj M; Bedoya F; Frigault MJ; Maus MV
    Curr Hematol Malig Rep; 2017 Apr; 12(2):119-125. PubMed ID: 28233151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement.
    Zhang Y; Zhang C; Zhou J; Zhang J; Chen X; Chen J; Wang P; Sun X; Lou X; Qi W; Kang L; Yu L; Wu D; Li C
    Front Immunol; 2021; 12():552429. PubMed ID: 33717057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Directed targeting of B-cell maturation antigen-specific CAR T cells by bioinformatic approaches: From in-silico to in-vitro.
    Moazzeni A; Kheirandish M; Khamisipour G; Rahbarizadeh F
    Immunobiology; 2023 May; 228(3):152376. PubMed ID: 37058845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
    Ferment B; Arnulf B
    Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
    Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
    Front Immunol; 2019; 10():1149. PubMed ID: 31178870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties.
    Hanssens H; Meeus F; Gesquiere EL; Puttemans J; De Vlaeminck Y; De Veirman K; Breckpot K; Devoogdt N
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.
    Wang T; Yang Y; Ma L; Feng R; Li J; Zhang C; Bai J; Ding Y; Liu G; Wu F; Lu X; Feng S; Li Z; He T; Li J; Liu H
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39313307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
    Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
    Front Immunol; 2021; 12():720571. PubMed ID: 34421924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
    Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN
    Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.